ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
폐질환 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 569억 8,000만 달러에서 2026년에는 600억 7,000만 달러에 이르고, CAGR 5.4%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 천식 환자 증가, 만성폐쇄성폐질환(COPD) 발병률 증가, 도시 대기오염 악화, 약물 전달 기술 보급, 호흡기 질환 진단 기술 향상 등을 꼽을 수 있습니다.
폐질환 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 741억 4,000만 달러에 이르고, CAGR은 5.4%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 고령화 인구 증가, 생물학적 폐질환 치료제 확대, 정밀 호흡기 의료 도입, 흡연 관련 질환 증가, 흡입 요법 접근성 개선 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 표적 호흡기 치료의 도입 증가, 복합 흡입 요법의 성장, 장기적인 질병 관리에 대한 관심 증가, 생물학적 제제 기반 폐질환 치료제의 확대, 개인 맞춤형 호흡기 치료로의 전환 등이 있습니다.
호흡기 질환의 발생률 증가가 폐질환 치료제 시장 확대를 견인할 것으로 예측됩니다. 호흡기 질환이란 폐와 기도에 영향을 미쳐 정상적인 호흡과 산소 교환을 방해하는 병태를 말합니다. 흡연율 증가는 폐 손상과 만성 질환을 유발하기 때문에 이러한 질병은 증가 추세에 있습니다. 폐질환 치료제는 폐 기능 개선, 염증 완화, 기도폐색 완화를 통해 호흡을 개선하기 때문에 호흡기 질환 치료에 필수적입니다. 예를 들어, 2025년 5월 미국 질병통제예방센터(CDC)가 발표한 보고서에 따르면, 2023년 18세 이상 성인의 COPD(만성폐쇄성폐질환) 연령 조정 유병률은 3.8%로 여성(4.1%)이 남성(3.4%)보다 더 높은 수치를 보였습니다. 더 높은 수치를 보였습니다. COPD의 유병률은 연령에 따라 현저하게 증가하여 18-24세에서는 0.4%인 반면, 75세 이상에서는 10.5%에 이르렀습니다. 이처럼 호흡기 질환에 대한 부담이 증가하면서 폐질환 치료제에 대한 수요가 증가하고 있습니다.
폐질환 치료제 시장의 주요 기업들은 COPD 유지요법에서 기관지 확장 작용과 비스테로이드성 항염증 작용을 단일 분자에 통합하기 위해 흡입 투여를 통한 PDE3와 PDE4의 이중 억제와 같은 치료 기술의 진보를 우선시하고 있습니다. 이 이중 억제 작용으로 기도 확장 및 폐렴 억제 효과를 동시에 달성하여 기존 치료제보다 강력하게 COPD의 지속적 증상에 대처하는 동시에, 복잡한 흡입 방법이 필요 없어 투여가 간편합니다. 예를 들어, 영국 바이오 제약사 베로나 파마는 2024년 6월 오투바이아(엔시펜트린)에 대해 미국 FDA의 승인을 받았습니다. 이는 20여년만에 승인된 최초의 이중 작용기전을 가진 흡입 치료제로서, 이중 작용기전을 가진 최초의 흡입 치료제가 될 것입니다. 표준 제트 분무기로 투여되는 오투바이아는 단회 투여로 기관지 확장 및 항염증 효과를 나타내며, ENHANCE 임상 3상 시험에서 단독요법 또는 다른 유지요법과의 병용요법에서 강력한 임상결과를 보였습니다. 2024년 3분기까지 미국 내 전문 약국을 통해 판매될 예정입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Pulmonary medications are drugs that focus on the respiratory system to enhance lung performance, decrease inflammation, and control airway conditions. They treat disorders like asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and various other respiratory diseases.
The primary drug classes for pulmonary treatments include inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short-acting beta-2 agonists, and others. Inhaled corticosteroids serve as anti-inflammatory agents delivered straight to the lungs through inhalers, helping control chronic respiratory issues like asthma and COPD by decreasing airway inflammation and averting exacerbations. Key indications encompass asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and more, with distribution occurring via channels like retail pharmacies, online pharmacies, and hospital pharmacies.
Tariffs have affected the pulmonary drugs market by increasing the cost of imported active pharmaceutical ingredients, inhalation-grade excipients, and specialized delivery device components. These impacts have been most pronounced in inhaled corticosteroid and biologic pulmonary drug segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have faced supply chain disruptions due to device component imports. However, tariffs have encouraged local API production and domestic inhaler manufacturing, supporting supply resilience and pricing stability.
The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides pulmonary drugs market statistics, including pulmonary drugs industry global market size, regional shares, competitors with a pulmonary drugs market share, detailed pulmonary drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. This pulmonary drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pulmonary drugs market size has grown strongly in recent years. It will grow from $56.98 billion in 2025 to $60.07 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing asthma prevalence, rising COPD incidence, urban air pollution growth, expansion of inhalation drug delivery, improved diagnosis of respiratory diseases.
The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population growth, expansion of biologic pulmonary drugs, precision respiratory medicine adoption, increasing smoking-related disorders, improved access to inhaled therapies. Major trends in the forecast period include rising adoption of targeted respiratory therapies, growth of combination inhalation treatments, increasing focus on long-term disease control, expansion of biologic-based pulmonary drugs, shift toward personalized respiratory care.
The rising incidence of respiratory diseases is anticipated to drive expansion in the pulmonary drugs market. Respiratory disorders encompass medical conditions that impact the lungs and airways, hindering normal breathing and oxygen exchange. These disorders are on the rise due to increasing smoking rates, which cause lung damage and chronic illnesses. Pulmonary drugs are essential for treating respiratory disorders, as they enhance lung function, alleviate inflammation, and ease airway blockages to improve breathing. For instance, in May 2025, the Centers for Disease Control and Prevention-a U.S. government agency-reported that in 2023, the age-adjusted prevalence of COPD among adults aged 18 and older stood at 3.8%, higher among women (4.1%) than men (3.4%). COPD rates increased significantly with age, from 0.4% in those aged 18-24 to 10.5% in individuals 75 and older. Thus, the growing burden of respiratory diseases is fueling demand for pulmonary drugs.
Major companies in the pulmonary drugs market are prioritizing therapeutic advancements, like dual PDE3 and PDE4 inhibition through inhaled administration, to merge bronchodilator and non-steroidal anti-inflammatory actions into one molecule for COPD maintenance therapy. This dual inhibition achieves concurrent airway dilation and suppression of lung inflammation, tackling ongoing COPD symptoms more potently than conventional options while streamlining dosing without needing intricate inhalation methods. For example, Verona Pharma plc, a UK biopharmaceutical firm, secured U.S. FDA approval in June 2024 for Ohtuvayre (ensifentrine), marking the first inhaled treatment with this dual-action mechanism in over two decades. Administered via a standard jet nebulizer, Ohtuvayre delivers bronchodilator and anti-inflammatory effects in a single dose, demonstrating strong clinical results as monotherapy or alongside other maintenance therapies in the Phase 3 ENHANCE trials, with availability projected through U.S. specialty pharmacies by Q3 2024.
In September 2024, Roivant Sciences Ltd., a US-based biotechnology company, acquired a pulmonary hypertension medicine from Bayer AG for an undisclosed sum. Through this acquisition, Roivant seeks to broaden its respiratory portfolio and push forward novel therapies for pulmonary hypertension, improving patient results and tackling unmet medical needs. Bayer AG, a Germany-based firm, produces pulmonary drugs, including therapies for respiratory issues like pulmonary hypertension.
Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.
North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pulmonary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pulmonary Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pulmonary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pulmonary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulmonary drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: Inhaled Corticosteroids; Long Acting Beta-2 Agonists; Antihistamines; Vasodilators; Short Acting Beta-2 Agonists; Other Drug Classes
2) By Indication: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Allergic Rhinitis; Pulmonary Arterial Hypertension; Cystic Fibrosis; Other Indications
3) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospitals Pharmacies
Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone; Budesonide; Fluticasone; Mometasone; Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol; Formoterol; Indacaterol; Olodaterol; Vilanterol
3) By Antihistamines: Cetirizine; Loratadine; Fexofenadine; Diphenhydramine; Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists; Phosphodiesterase-5 Inhibitors; Prostacyclin Analogues
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Rising Adoption Of Targeted Respiratory Therapies
4.2.2 Growth Of Combination Inhalation Treatments
4.2.3 Increasing Focus On Long-Term Disease Control
4.2.4 Expansion Of Biologic-Based Pulmonary Drugs
4.2.5 Shift Toward Personalized Respiratory Care
5. Pulmonary Drugs Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Pulmonology Clinics
5.3 Specialty Respiratory Centers
5.4 Homecare Providers
5.5 Ambulatory Care Centers
6. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Pulmonary Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Pulmonary Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Pulmonary Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Pulmonary Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Pulmonary Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Pulmonary Drugs Market Segmentation
9.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
9.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Pulmonary Drugs Market
12.1. China Pulmonary Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Pulmonary Drugs Market
13.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Pulmonary Drugs Market
14.1. Japan Pulmonary Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Pulmonary Drugs Market
15.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Pulmonary Drugs Market
16.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Pulmonary Drugs Market
17.1. South Korea Pulmonary Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Pulmonary Drugs Market
18.1. Taiwan Pulmonary Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Pulmonary Drugs Market
19.1. South East Asia Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Pulmonary Drugs Market
20.1. Western Europe Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Pulmonary Drugs Market
21.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Pulmonary Drugs Market
22.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Pulmonary Drugs Market
23.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Pulmonary Drugs Market
24.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Pulmonary Drugs Market
25.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Pulmonary Drugs Market
26.1. Eastern Europe Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Pulmonary Drugs Market
27.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Pulmonary Drugs Market
28.1. North America Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Pulmonary Drugs Market
29.1. USA Pulmonary Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Pulmonary Drugs Market
30.1. Canada Pulmonary Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Pulmonary Drugs Market
31.1. South America Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Pulmonary Drugs Market
32.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Pulmonary Drugs Market
33.1. Middle East Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Pulmonary Drugs Market
34.1. Africa Pulmonary Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Pulmonary Drugs Market Regulatory and Investment Landscape
36. Pulmonary Drugs Market Competitive Landscape And Company Profiles
36.1. Pulmonary Drugs Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Pulmonary Drugs Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Pulmonary Drugs Market Company Profiles
36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Chiesi Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
37. Pulmonary Drugs Market Other Major And Innovative Companies
